153 related articles for article (PubMed ID: 35599277)
1. Therapeutic natural compounds Enzastaurin and Palbociclib inhibit MASTL kinase activity preventing breast cancer cell proliferation.
Polisety A; Misra G; Rajawat J; Katiyar A; Singh H; Bhatt AN
Med Oncol; 2022 May; 39(5):100. PubMed ID: 35599277
[TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of MASTL kinase activity induces apoptosis in breast cancer.
Misra G; Rajawat J; Pal R; Smith JC; Kumar A
Life Sci; 2023 Dec; 334():122250. PubMed ID: 37931742
[TBL] [Abstract][Full Text] [Related]
3. E2F8 confers cisplatin resistance to ER+ breast cancer cells via transcriptionally activating MASTL.
Tian J; Lin Y; Yu J
Biomed Pharmacother; 2017 Aug; 92():919-926. PubMed ID: 28605876
[TBL] [Abstract][Full Text] [Related]
4. MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells.
Yoon YN; Choe MH; Jung KY; Hwang SG; Oh JS; Kim JS
BMC Cancer; 2018 Jul; 18(1):716. PubMed ID: 29976159
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of Microtubule Associated Serine/threonine Kinase Like Expression Inhibits Gastric Cancer Cell Growth and Induces Apoptosis by Activation of ERK1/2 and Inactivation of NF-κB Signaling.
An CX; Xie SP; Li HL; Hu YH; Niu R; Zhang LJ; Jiang Y; Li Q; Zhou YN
Curr Med Sci; 2021 Feb; 41(1):108-117. PubMed ID: 33582914
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.
Álvarez-Fernández M; Sanz-Flores M; Sanz-Castillo B; Salazar-Roa M; Partida D; Zapatero-Solana E; Ali HR; Manchado E; Lowe S; VanArsdale T; Shields D; Caldas C; Quintela-Fandino M; Malumbres M
Cell Death Differ; 2018 May; 25(5):828-840. PubMed ID: 29229993
[TBL] [Abstract][Full Text] [Related]
7. MASTL overexpression promotes chromosome instability and metastasis in breast cancer.
Rogers S; McCloy RA; Parker BL; Gallego-Ortega D; Law AMK; Chin VT; Conway JRW; Fey D; Millar EKA; O'Toole S; Deng N; Swarbrick A; Chastain PD; Cesare AJ; Timpson P; Caldon CE; Croucher DR; James DE; Watkins DN; Burgess A
Oncogene; 2018 Aug; 37(33):4518-4533. PubMed ID: 29743597
[TBL] [Abstract][Full Text] [Related]
8. MASTL: A novel therapeutic target for Cancer Malignancy.
Fatima I; Singh AB; Dhawan P
Cancer Med; 2020 Sep; 9(17):6322-6329. PubMed ID: 32692487
[TBL] [Abstract][Full Text] [Related]
9. Mastl kinase, a promising therapeutic target, promotes cancer recurrence.
Wang L; Luong VQ; Giannini PJ; Peng A
Oncotarget; 2014 Nov; 5(22):11479-89. PubMed ID: 25373736
[TBL] [Abstract][Full Text] [Related]
10. MASTL promotes cell contractility and motility through kinase-independent signaling.
Taskinen ME; Närvä E; Conway JRW; Hinojosa LS; Lilla S; Mai A; De Franceschi N; Elo LL; Grosse R; Zanivan S; Norman JC; Ivaska J
J Cell Biol; 2020 Jun; 219(6):. PubMed ID: 32311005
[TBL] [Abstract][Full Text] [Related]
11. AKT Regulates Mitotic Progression of Mammalian Cells by Phosphorylating MASTL, Leading to Protein Phosphatase 2A Inactivation.
Reshi I; Nisa MU; Farooq U; Gillani SQ; Bhat SA; Sarwar Z; Nabi N; Fazili KM; Andrabi S
Mol Cell Biol; 2020 Apr; 40(10):. PubMed ID: 32123010
[TBL] [Abstract][Full Text] [Related]
12. Kinase-Independent Functions of MASTL in Cancer: A New Perspective on MASTL Targeting.
Conway JRW; Närvä E; Taskinen ME; Ivaska J
Cells; 2020 Jul; 9(7):. PubMed ID: 32640605
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Characterization of a Novel MASTL Inhibitor MKI-2 Targeting MASTL-PP2A in Breast Cancer Cells and Oocytes.
Kang M; Kim C; Leem J; Kim YH; Kwon YJ; Yoon YN; Chae CH; Ahn J; Jung KY; Oh JS; Kim JS
Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358073
[TBL] [Abstract][Full Text] [Related]
14. MASTL is the human orthologue of Greatwall kinase that facilitates mitotic entry, anaphase and cytokinesis.
Voets E; Wolthuis RM
Cell Cycle; 2010 Sep; 9(17):3591-601. PubMed ID: 20818157
[TBL] [Abstract][Full Text] [Related]
15. Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells.
Cetti E; Di Marco T; Mauro G; Mazzoni M; Lecis D; Minna E; Gioiosa L; Brich S; Pagliardini S; Borrello MG; Pruneri G; Anania MC; Greco A
Cancer Lett; 2019 Feb; 442():362-372. PubMed ID: 30445205
[TBL] [Abstract][Full Text] [Related]
16. Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells.
Maskey RS; Wang F; Lehman E; Wang Y; Emmanuel N; Zhong W; Jin G; Abraham RT; Arndt KT; Myers JS; Mazurek A
Cell Cycle; 2021 Jan; 20(1):65-80. PubMed ID: 33356791
[TBL] [Abstract][Full Text] [Related]
17. SILAC kinase screen identifies potential MASTL substrates.
Marzec KA; Rogers S; McCloy R; Parker BL; James DE; Watkins DN; Burgess A
Sci Rep; 2022 Jun; 12(1):10568. PubMed ID: 35732702
[TBL] [Abstract][Full Text] [Related]
18. Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
Chen L; Yang G; Dong H
Med Sci Monit; 2019 Jan; 25():77-86. PubMed ID: 30605443
[TBL] [Abstract][Full Text] [Related]
19. MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling.
Uppada SB; Gowrikumar S; Ahmad R; Kumar B; Szeglin B; Chen X; Smith JJ; Batra SK; Singh AB; Dhawan P
Mol Cancer; 2018 Aug; 17(1):111. PubMed ID: 30068336
[TBL] [Abstract][Full Text] [Related]
20. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
Martinez R; Blasina A; Hallin JF; Hu W; Rymer I; Fan J; Hoffman RL; Murphy S; Marx M; Yanochko G; Trajkovic D; Dinh D; Timofeevski S; Zhu Z; Sun P; Lappin PB; Murray BW
PLoS One; 2015; 10(9):e0138616. PubMed ID: 26398286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
